Compugen (CGEN) Stock
Clinical stage biotech firm using computational drug discovery. Here's the price, business snapshot, and what's worth knowing about Compugen in August 2026.
Compugen Ltd (CGEN) is a clinical-stage biotechnology company that applies computational discovery to identify therapeutic targets, biomarkers and novel drug candidates, with a focus on immuno-oncology and precision medicine. The company leverages in‑house predictive platforms to nominate targets and advance a pipeline that can be progressed internally or licensed to partners. With a market capitalisation around $164.62M, Compugen is a small‑cap, development‑stage firm — potential upside from clinical or partnership milestones is matched by execution, funding and regulatory risks. Investors should note the firm may rely on collaborations, milestone payments or equity financing to fund development. Financial results and pipeline progress can be volatile; therapeutic development is lengthy and uncertain. This summary is for educational purposes only and is not personal investment advice. Investors should carry out their own research and consider risk tolerance before making investment decisions.
About This Stock
COMPUGEN
CGEN
Current Price
$2.39
Potential 12 Month Profit
125.19%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Ticker
CGEN
Market Cap
$231.14M
Potential 12 Month Profit
125.19%
Sector
Healthcare
Industry
Biotechnology & Medical Research
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts strongly recommend buying Compugen's stock with a target price of $5, indicating significant growth potential.
Financial Health
Compugen Ltd is performing well in revenue and profit margins, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Computational Discovery Edge
Compugen’s predictive platforms help nominate novel targets and biomarkers, a potential differentiator — though platform validation and clinical proof remain essential.
Milestones Drive Moves
Clinical readouts, partnerships or licensing deals can materially affect value; investors should expect volatility and monitor news flow closely.
Partnering Opportunities
The company’s model includes partnering to commercialise assets, which can accelerate development but depends on negotiation outcomes and counterparty execution.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.